ArticleBlood advances2022
Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.British journal of haematology · 2026Article
- Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis.Haematologica · 2026Review
- When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.British journal of haematology · 2026Review
- Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib.Journal of clinical medicine · 2025Article
- JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms.Nature communications · 2025Article
- Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis.Blood neoplasia · 2025Article
- The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis.Haematologica · 2024Article
- Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.Bone marrow transplantation · 2024Observational
- Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.Cancers · 2024Review
- Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Blood cancer journal · 2023Review
- SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.Clinical lymphoma, myeloma & leukemia · 2023Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.